*September 2024*
Osimertinib is now an FDA-approved therapy for stage III NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations that did not progress during or following platinum-based chemoradiation.
- The FDA approved osimertinib (Tagrisso) for the treatment of patients with stage III EGFR-mutated non–small cell lung cancer (NSCLC) whose disease did not progress during or following concurrent or sequential platinum-based chemoradiation.
- The approval is supported by the phase 3 LAURA trial (NCT03521154).
- Osimertinib led to statistically significant improvements in progression-free survival (PFS).
Osimertinib has gained FDA approval for the treatment of adult patients with locally advanced, unresectable, stage III NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.1
Data from the phase 3 LAURA trial support this regulatory decision. Findings presented at the 2024 American Society of Clinical Oncology Annual Meeting showed there to be a dramatic improvement in PFS for those taking osimertinib with 39.1 months (95% CI, 31.5-not calculable) vs 5.6 months (95% CI, 3.7-7.4). The 12-month PFS rate was 74% with osimertinib vs 22% with placebo, and the 24-month PFS rates were 65% vs 13%, respectively.2 Read more.
